Antibody Detection of Deltanoid-Resistant Leukemia Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to distinguish between leukemia cells resistant and susceptible to differentiation mediated by deltanoids, hindering effective therapy selection in acute myeloid leukemia treatment.
Innovation Solution
A method using antibodies, specifically scFv format antibodies obtained through phage display, to detect surface antigens on leukemia cells, differentiating between resistant and susceptible cells by employing SEQ ID NO: 1 for detection and SEQ ID NO: 2 as a negative control, preferably through flow cytometry or ELISA-type assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then general leukemia detection is possible, but differentiation between deltanoid-resistant and deltanoid-susceptible cells cannot be achieved
Solution Approach 1:
The patent employs flow cytometry with fluorescently labeled antibodies that bind to surface antigens on leukemia cells. The fluorescent signals produce distinct color/fluorescence patterns that allow visual and instrumental differentiation between deltanoid-resistant and deltanoid-susceptible cell populations, directly resolving the measurement precision limitation of conventional methods.
Solution Approach 2:
The patent introduces specific antibodies as intermediary agents that recognize and bind to surface antigens uniquely expressed on deltanoid-resistant leukemia cells. These antibodies serve as mediators between the diagnostic system and the target cells, enabling specific identification and differentiation that conventional direct staining methods cannot achieve.
2Loss of time
If rapid therapy selection is implemented, then treatment time is reduced, but accuracy in identifying susceptible cells may be compromised
Solution Approach 1:
The patent performs preliminary characterization of leukemia cells by detecting surface antigen expression patterns before initiating deltanoid therapy. By pre-identifying the presence or absence of specific surface antigens using flow cytometry, the system determines cell susceptibility in advance, enabling rapid and accurate therapy selection without compromising diagnostic accuracy despite the accelerated timeline.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid evaluation of patient cell susceptibility to deltanoid therapy, facilitating accelerated selection of correct and individually matched treatment methods, thereby improving treatment outcomes for acute myeloid leukemia.
Implementation Method 1
antibody comprising SEQ ID NO: 1 is used for the detection
Data Source
Figure 1~2a
Figure 2b~3
Figure 4a
AI summary
The present invention relates to a method and a kit and antibodies utilized therein, allowing to distinguish between leukemia cells resistant to and leukemia cells susceptible to differentiation induced by deltanoids.